Regulatory product record
NEXGARD
Product identity, ingredients and source provenance from the regulatory catalogue. Linked clinical evidence has a separate review status.
Product identity
- Brand name
- NEXGARD
- DIN
- 02427451
- DPD drug code
- 91198
- Regulatory category
- APPROVED_VET_DRUG
- Market status
- MARKETED
- Route(s)
- ORAL
- Pharmaceutical form(s)
- TABLET (CHEWABLE)
- Ingredients
- AFOXOLANER (68 MG)
- Species (DPD record)
- DOGS
- Company
- BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. (DIN owner)
Source and provenance
- Source dataset
- health_canada_dpd_marketed
- Source snapshot date
- Not available in this source
- Source record key
- 91198
- Archive fingerprint (SHA-256)
- 85cc3ce208af3aa57018c3d14d83f90220c436baef7455384b6d48d9774e1c88
Linked clinical reference
Clinical entries are linked through the active molecule. Check their species, formulation, source and review status separately from this product record.
Clinical evidence
Dose regimens0
No dose regimens recorded for this species selection.
Adverse effects200
These are counts of spontaneously reported events, not proven adverse effects, causal relationships, or incidence rates.
Bars compare report counts within each species; they do not show incidence.
More reportsFewer reportsDog
- Vomiting15,966 reports
- Diarrhoea6,119 reports
- Lethargy (see also Central nervous system depression in 'Neurological')5,703 reports
- Lack of efficacy (ectoparasite) - tick NOS4,987 reports
- Lack of efficacy (ectoparasite) - flea4,527 reports
- Seizure NOS4,402 reports
- Lack of efficacy (bacteria) - Borrelia3,553 reports
- Lack of efficacy (tick)3,389 reports
- Skin disorders NOS2,625 reports
- Lack of efficacy (bacteria) - NOS2,606 reports
- Pruritus2,443 reports
- Itching2,148 reports
Cat
- Vomiting14 reports
- Administration error NOS8 reports
- Lethargy (see also Central nervous system depression in Neurological)7 reports
- Hyperactivity6 reports
- Not eating6 reports
- Inappetence5 reports
- Itching5 reports
- Lack of efficacy (ectoparasite) - flea5 reports
- Lethargy (see also Central nervous system depression in 'Neurological')5 reports
- Panting5 reports
- Accidental exposure4 reports
- Ataxia4 reports
Literature references20
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- Efficacy of afoxolaner (NexGard®) for the treatment of myiasis caused by the zoonotic tumbu fly, Cordylobia anthropophaga, in domestic dogs under field conditions.
Study summary not available in the imported record. Open the original citation to review the study.
- Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGard(®) PLUS), or lotilaner (Credelio Quattro™).
Study summary not available in the imported record. Open the original citation to review the study.
- Patterns of antiparasitic usage in Golden Retriever breed of dogs: A 9-year cohort study.
Study summary not available in the imported record. Open the original citation to review the study.
- Saving a species, one mite at a time: efficacy of afoxolaner (NexGard®) against Macronyssidae mites in the critically endangered Aeolian wall lizard (Podarcis raffonei).
Study summary not available in the imported record. Open the original citation to review the study.
- Comparative efficacy of six monthly doses of Simparica Trio(®) (sarolaner, moxidectin, and pyrantel chewable tablets) versus NexGard(®) Plus (afoxolaner, moxidectin, and pyrantel chewable tablets) against a macrocyclic lactone-resistant Dirofilaria immitis isolate in dogs.
Study summary not available in the imported record. Open the original citation to review the study.
Sources: PubMed, National Library of Medicine; openFDA, U.S. Food and Drug Administration.